MA44479A - Arn transrepliquant - Google Patents

Arn transrepliquant

Info

Publication number
MA44479A
MA44479A MA044479A MA44479A MA44479A MA 44479 A MA44479 A MA 44479A MA 044479 A MA044479 A MA 044479A MA 44479 A MA44479 A MA 44479A MA 44479 A MA44479 A MA 44479A
Authority
MA
Morocco
Prior art keywords
transreplicant
rna
transreplicant rna
Prior art date
Application number
MA044479A
Other languages
English (en)
Other versions
MA44479B1 (fr
Inventor
Tim Beissert
Mario Perkovic
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MA44479A publication Critical patent/MA44479A/fr
Publication of MA44479B1 publication Critical patent/MA44479B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MA44479A 2016-03-21 2017-03-13 Arn transrepliquant MA44479B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/056160 WO2017162265A1 (fr) 2016-03-21 2016-03-21 Arn à réplication trans
PCT/EP2017/055813 WO2017162461A1 (fr) 2016-03-21 2017-03-13 Arn à réplication trans

Publications (2)

Publication Number Publication Date
MA44479A true MA44479A (fr) 2021-04-21
MA44479B1 MA44479B1 (fr) 2021-11-30

Family

ID=55586324

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44479A MA44479B1 (fr) 2016-03-21 2017-03-13 Arn transrepliquant

Country Status (26)

Country Link
US (2) US12338448B2 (fr)
EP (2) EP3433368B1 (fr)
JP (2) JP7105193B2 (fr)
KR (1) KR102441725B1 (fr)
CN (2) CN109328233B (fr)
AU (1) AU2017236240B2 (fr)
BR (1) BR112018068391A2 (fr)
CY (1) CY1124689T1 (fr)
DK (1) DK3433368T3 (fr)
ES (1) ES2896927T3 (fr)
HR (1) HRP20211715T1 (fr)
HU (1) HUE058889T2 (fr)
IL (1) IL261327B2 (fr)
LT (1) LT3433368T (fr)
MA (1) MA44479B1 (fr)
MD (1) MD3433368T2 (fr)
MX (1) MX2018011384A (fr)
PL (1) PL3433368T3 (fr)
PT (1) PT3433368T (fr)
RS (1) RS62543B1 (fr)
RU (1) RU2752580C2 (fr)
SG (1) SG11201807378SA (fr)
SI (1) SI3433368T1 (fr)
SM (1) SMT202100634T1 (fr)
WO (2) WO2017162265A1 (fr)
ZA (2) ZA201805520B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017070624A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre des maladies tropicales
EP3681904A1 (fr) * 2017-09-13 2020-07-22 Biontech Cell&Gene Therapies GmbH Réplicon d'arn permettant d'exprimer un récepteur de lymphocyte t ou un récepteur de lymphocyte t artificiel
EP3681993B1 (fr) * 2017-09-13 2026-04-01 BioNTech SE Réplicon d'arn pour la reprogrammation de cellules somatiques
WO2019055807A1 (fr) 2017-09-14 2019-03-21 Modernatx, Inc. Vaccins à arn contre le virus zika
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN114072513A (zh) * 2019-06-27 2022-02-18 Emd密理博公司 用表达永生化蛋白的自我复制型rna载体的细胞扩增
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
CA3167611A1 (fr) 2020-02-13 2021-08-19 Etienne Simon-Loriere Vaccin a base d'acide nucleique contre le coronavirus sars-cov-2
KR102462990B1 (ko) 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
WO2022002783A1 (fr) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
WO2022099003A1 (fr) 2020-11-06 2022-05-12 Sanofi Nanoparticules lipidiques pour l'administration de vaccins à arnm
GB202020064D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020061D0 (en) 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
GB202020063D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
CN112852841A (zh) 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
CA3212653A1 (fr) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Compositions immunogenes
US20240336672A1 (en) 2021-04-26 2024-10-10 Institut Pasteur Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
US20240240201A1 (en) * 2021-05-04 2024-07-18 Mogrify Limited Cell conversion
WO2022248353A1 (fr) 2021-05-24 2022-12-01 Glaxosmithkline Biologicals Sa Adjuvants
US12570977B2 (en) * 2021-06-12 2026-03-10 Mello Biotech Taiwan Co., Ltd. mRNA composition and production method for use in anti-viral and anti-cancer vaccines
EP4355308A1 (fr) 2021-06-18 2024-04-24 Sanofi Vaccins multivalents contre la grippe
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
EP4387596A1 (fr) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023025404A1 (fr) 2021-08-24 2023-03-02 BioNTech SE Technologies de transcription in vitro
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
EP4419708A1 (fr) 2021-10-18 2024-08-28 BioNTech SE Procédés pour déterminer les mutations permettant d'augmenter la fonction de l'arn modifié réplicable et compositions connexes et leur utilisation
EP4285933A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Complexes oligosaccharides et utilisations
WO2023067123A1 (fr) 2021-10-22 2023-04-27 BioNTech SE Complexes d'oligosaccharides et leurs utilisations
US20240417418A1 (en) 2021-10-22 2024-12-19 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169534A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Complexes oligosaccharides et utilisations
AU2022369405A1 (en) 2021-10-22 2024-05-09 BioNTech SE Oligosaccharide compounds and complexes
EP4169580A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide
EP4286004A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide de disulfure
EP4286394A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide
EP4186528A1 (fr) 2021-11-30 2023-05-31 BioNTech SE Complexes oligosaccharides et utilisations
EP4402150A1 (fr) 2021-10-22 2024-07-24 BioNTech SE Composés et complexes oligosaccharidiques
JP2024543721A (ja) 2021-10-22 2024-11-22 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4169579A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide de disulfure
EP4285932A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Complexes oligosaccharides et utilisations
EP4169578A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide
EP4286003A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide
MX2024005462A (es) 2021-11-05 2024-05-22 Sanofi Sa Vacuna de arn del virus respiratorio sincitial.
WO2023083434A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Arn codant pour la peptidoglycane hydrolase et son utilisation pour le traitement d'une infection bactérienne
JP2025500880A (ja) 2021-12-17 2025-01-15 サノフイ ライム病ｒｎａワクチン
CA3256624A1 (fr) 2022-05-06 2023-11-09 Sanofi Séquences de signaux pour vaccins à base d'acides nucléiques
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
JP2025529906A (ja) 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
WO2024068674A1 (fr) 2022-09-26 2024-04-04 BioNTech SE Complexes d'acide nucléique et leurs utilisations
WO2024086549A1 (fr) * 2022-10-17 2024-04-25 The University Of North Carolina At Chapel Hill Alphavirus chimériques pour évolution dirigée
WO2024084462A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Complexes d'acide nucléique et leurs utilisations
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides
KR20250099727A (ko) 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
CN120548367A (zh) 2022-11-18 2025-08-26 波士顿大学董事会 自复制rna及其用途
CN120659802A (zh) 2022-12-15 2025-09-16 赛诺菲巴斯德有限公司 mRNA重组加帽酶
WO2024133160A1 (fr) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Compositions pour le traitement de l'hépatite b
WO2024133550A1 (fr) 2022-12-22 2024-06-27 Vector Biopharma Ag Système d'auto-amplification eucaryote
EP4669348A1 (fr) 2023-02-24 2025-12-31 BioNTech SE Compositions immunogènes
CN120813371A (zh) 2023-03-02 2025-10-17 赛诺菲巴斯德有限公司 用于在衣原体病的治疗中使用的组合物
EP4442276A1 (fr) 2023-04-07 2024-10-09 Institut Pasteur Anticorps combinés contre les sarcovirus et leurs utilisations
US12502424B2 (en) 2023-05-05 2025-12-23 Sanofi Pasteur Inc. Compositions for use in treatment of acne
WO2024231565A1 (fr) 2023-05-10 2024-11-14 Sanofi Vaccins à arnm respiratoire combinés
EP4713009A1 (fr) 2023-05-17 2026-03-25 Institut Pasteur Hétérodimère de protéines a16 et g9 de poxvirus en tant qu'agent immunogène
EP4474015A1 (fr) 2023-06-05 2024-12-11 Veterna Srl Pharmacon de vaccin à arn de type noda et sa production et ses utilisations
AU2024291595A1 (en) 2023-07-19 2026-03-05 Sanofi Porphyromonas gingivalis antigenic constructs
WO2025027089A1 (fr) 2023-08-01 2025-02-06 BioNTech SE Thioplipides ionisables et leurs utilisations
WO2025026545A1 (fr) 2023-08-01 2025-02-06 BioNTech SE Thioplipides ionisables et utilisations associées
EP4520334A1 (fr) 2023-09-07 2025-03-12 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
WO2025052001A1 (fr) 2023-09-07 2025-03-13 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
KR20250055419A (ko) * 2023-10-16 2025-04-24 한국생명공학연구원 단백질 번역 효율 향상용 RNA 구조체, 이를 포함하는 mRNA 구조체 및 이의 용도
WO2025096982A1 (fr) * 2023-11-02 2025-05-08 Amplitude Therapeutics, Inc. Arn transamplifiant comportant des nucléobases chimiquement modifiées
WO2025124711A1 (fr) 2023-12-13 2025-06-19 BioNTech SE Compositions de glycolipides
WO2025134066A1 (fr) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Lipides ionisables
WO2025134062A2 (fr) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Lipides ionisables
WO2025153707A1 (fr) 2024-01-19 2025-07-24 Spikimm Anticorps monoclonaux neutralisants à large spectre dirigés contre le sars-cov-2 et leurs utilisations
WO2025157249A1 (fr) * 2024-01-24 2025-07-31 南京金斯瑞生物科技有限公司 Arn auto-réplicatif et son utilisation
WO2025217136A2 (fr) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Arn trans-amplificateurs codant pour des immunomodulateurs
EP4656648A1 (fr) 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Composés immunomodulateurs à base de thiourée et d'urée et leurs utilisations
WO2025262460A1 (fr) 2024-06-21 2025-12-26 BioNTech SE Compositions lipidiques pour l'administration d'acides nucléiques
WO2026008743A1 (fr) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Polymère polyanionique soluble dans l'eau en tant qu'adjuvant pour acide nucléique formulé par un support
WO2026033380A1 (fr) 2024-08-05 2026-02-12 BioNTech SE Processus de préparation de complexes oligosaccharidiques
EP4696782A1 (fr) 2024-08-14 2026-02-18 Starvax One B.V. Replicons d'arn divise ameliores

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
KR20020013508A (ko) 1999-03-09 2002-02-20 유니버시티 오브 플로리다 외래 서열을 발현시키기위한 다성분 ｒｎａ 벡터 시스템
MXPA03001680A (es) * 2000-08-29 2004-11-01 Wyeth Corp Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva.
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
EP1490494A1 (fr) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Procede pour concevoir des sequences d'acides nucleiques de synthese pour l'expression optimale de proteines dans une cellule hote
US7442381B2 (en) 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
EP2848692B1 (fr) * 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'alphavirus de vaccins contre le virus de la grippe
WO2008119827A1 (fr) * 2007-04-02 2008-10-09 Fit Biotech Oy Produits de synthèse transréplicases
CN104072561B (zh) 2007-06-19 2017-12-22 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
US8460913B2 (en) * 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
ES2840725T3 (es) 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (fr) 2009-08-05 2011-02-09 BioNTech AG Composition de vaccin comportant un ADN modifié 5'-Cap
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
MX342608B (es) * 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
MX2013002332A (es) 2010-08-31 2013-03-18 Novartis Ag Lipidos apropiados para suministro liposomal del arn que codifica la proteina.
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
SI4043040T1 (sl) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Mali liposomi za dostavo imunogen-kodirajoče RNA
WO2012051211A2 (fr) * 2010-10-11 2012-04-19 Novartis Ag Plateformes de délivrance d'antigènes
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
EP4115875A1 (fr) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes ayant un rapport n:p utile pour délivrance de molécules d'arn
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
EP2729165B1 (fr) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
RU2014118727A (ru) 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
CA2889659C (fr) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions et methodes pour le traitement d'infections par cytomegalovirus
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
SG11201405542UA (en) 2012-03-27 2014-10-30 Curevac Gmbh Artificial nucleic acid molecules
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2014071963A1 (fr) 2012-11-09 2014-05-15 Biontech Ag Procédé pour l'expression d'arn cellulaire
WO2014170493A2 (fr) * 2013-04-19 2014-10-23 Novartis Ag Vecteur d'alphavirus
WO2016005004A1 (fr) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilisation de séquences d'adn codant pour une séquence poly (a)
KR102762959B1 (ko) * 2017-09-13 2025-02-06 트론-트란슬라셔날레 온콜로기 안 데어 유니버시태츠메디진 데어 요하네스 구텐베르크-유니버시태트 마인츠 게마인뉘치게 게엠베하 세포에서 rna 발현을 향상시키는 방법

Also Published As

Publication number Publication date
EP3964584A1 (fr) 2022-03-09
JP2022020634A (ja) 2022-02-01
RU2018131783A3 (fr) 2020-07-14
PT3433368T (pt) 2021-11-15
HUE058889T2 (hu) 2022-09-28
CA3017285A1 (fr) 2017-09-28
MX2018011384A (es) 2019-02-13
CN109328233B (zh) 2022-10-11
JP2019509048A (ja) 2019-04-04
WO2017162461A1 (fr) 2017-09-28
US20250290095A1 (en) 2025-09-18
SG11201807378SA (en) 2018-10-30
AU2017236240B2 (en) 2022-11-17
US20200299724A1 (en) 2020-09-24
MA44479B1 (fr) 2021-11-30
ZA201805520B (en) 2019-11-27
SMT202100634T1 (it) 2022-01-10
RS62543B1 (sr) 2021-12-31
CN109328233A (zh) 2019-02-12
RU2018131783A (ru) 2020-04-22
CN115386596A (zh) 2022-11-25
US12338448B2 (en) 2025-06-24
RU2752580C2 (ru) 2021-07-29
AU2017236240A1 (en) 2018-09-20
LT3433368T (lt) 2021-11-25
ZA201905396B (en) 2021-03-31
IL261327B2 (en) 2024-08-01
WO2017162265A1 (fr) 2017-09-28
SI3433368T1 (sl) 2022-01-31
BR112018068391A2 (pt) 2019-01-15
DK3433368T3 (da) 2021-11-15
ES2896927T3 (es) 2022-02-28
KR20180127360A (ko) 2018-11-28
KR102441725B1 (ko) 2022-09-08
IL261327B1 (en) 2024-04-01
CY1124689T1 (el) 2022-07-22
MD3433368T2 (ro) 2021-12-31
EP3433368A1 (fr) 2019-01-30
JP7421256B2 (ja) 2024-01-24
JP7105193B2 (ja) 2022-07-22
HRP20211715T1 (hr) 2022-02-18
IL261327A (en) 2018-10-31
PL3433368T3 (pl) 2021-12-27
EP3433368B1 (fr) 2021-10-06

Similar Documents

Publication Publication Date Title
MA44479A (fr) Arn transrepliquant
MA47680A (fr) Arn thérapeutique
DK3405050T3 (da) Børnesikret snusbeholder
EP3440949A4 (fr) Inhalateur d'arôme
EP3446605A4 (fr) Aspirateur à main
DK3436823T3 (da) Antigen-array
EP3455498A4 (fr) Injecteur de distribution de carburant
EP3445380C0 (fr) Bactériothérapie
EP3450133A4 (fr) Procédé de moulage par soufflage de liquide
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
EP3436590A4 (fr) Arn de transépissage (tsrna)
EP3402022A4 (fr) Pince-fil
EP3465295A4 (fr) Empilement de polariseurs
DK3445708T3 (da) Stigbøjle
EP3326949A4 (fr) Bobine
EP3402021A4 (fr) Pince-fil
DK3452590T3 (da) Plademagnet
DK3509963T3 (da) Pallecontainer
EP3478921A4 (fr) Agencement de cordon de traction
EP3475155A4 (fr) Hydroptère
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
EP3399976C0 (fr) Amphophiles de benzothiazole
EP3473285A4 (fr) Injecteur